Tibsovo Gets A Win In AML Following Servier Takeover
Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.
You may also be interested in...
The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.